华创医药周观点：202601医药业绩前瞻 2026/03/29

Core Viewpoint - The report emphasizes the growth potential in the pharmaceutical industry, particularly in innovative drugs, medical devices, and life sciences services, driven by domestic and international market dynamics [8][10][15]. Market Review - The CITIC Pharmaceutical Index rose by 1.49%, outperforming the CSI 300 Index by 2.9 percentage points, ranking 5th among 30 primary industries [6]. - Top-performing stocks included Meinuohua and Wanbangde, with increases of 40.73% and 38.81% respectively, while stocks like Keyuan Pharmaceutical and Changyao Tui saw declines of 19.92% and 18.18% [6][25]. Sector Insights and Investment Strategy - Innovative Drugs: China is becoming a significant player in global innovative drug development, with a notable increase in overseas licensing deals, suggesting a shift towards an "innovation-driven" revenue era [8]. - Medical Devices: The pressure from high-value consumables procurement is easing, and the industry is expected to see a recovery in revenue growth by Q3 2025. Companies are focusing on international expansion and technological upgrades [8][13]. - Life Sciences Services: The sector is witnessing a recovery in demand, with a projected increase in revenue starting from Q4 2024. The focus is on domestic and international market expansion [15][17]. - Traditional Chinese Medicine: The market for essential medicines is expected to grow, particularly as the new medical insurance directory expands coverage [9][18]. - Pharmacy Sector: The trend of prescription outflow is expected to accelerate, improving the competitive landscape for pharmacies [16]. Earnings Forecast for Q1 2026 - Various companies are projected to have modest revenue growth, with notable predictions including: - Kanglong Chemical: 10-15% revenue growth - Aier Eye Hospital: 0-10% revenue growth - Yifeng Pharmacy: 0-5% revenue growth [10]. Key Events in the Industry - The approval of Tezepelumab for asthma treatment in China marks a significant milestone for AstraZeneca and Amgen [24]. - The construction of the Longhua International Medical Device City aims to enhance the high-end medical device industry in China [23]. Conclusion - The pharmaceutical industry is poised for growth, driven by innovation, regulatory changes, and market dynamics, with specific sectors like innovative drugs and medical devices showing promising potential for investment [8][10][15].